Robert J Israel Selected Research

methylnaltrexone

1/2022	First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis.
9/2021	The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies.
1/2021	Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials.
1/2021	Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies.
3/2020	Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer.
1/2019	Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.
1/2018	Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.
1/2018	Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone.
8/2017	Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.
1/2017	Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Israel Research Topics

Disease

16	Opioid-Induced Constipation 01/2022 - 05/2008
12	Pain (Aches) 01/2022 - 05/2008
8	Neoplasms (Cancer) 01/2022 - 09/2009
7	Substance Withdrawal Syndrome (Withdrawal Symptoms) 09/2021 - 05/2006
4	Constipation 01/2021 - 05/2008
4	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2020 - 01/2018
3	Nausea 01/2021 - 08/2009
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2014
3	Body Weight (Weight, Body) 07/2015 - 05/2008
2	Vomiting 01/2021 - 08/2009
2	Circulating Neoplastic Cells 01/2020 - 01/2019
2	Diarrhea 01/2019 - 01/2017
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2019 - 01/2017
2	Abdominal Pain (Pain, Abdominal) 01/2019 - 11/2011
1	Fibrosis (Cirrhosis) 06/2022
1	COVID-19 12/2021
1	Brain Neoplasms (Brain Tumor) 09/2021
1	Injection Site Reaction 02/2020
1	Hypersensitivity (Allergy) 02/2020
1	Neutropenia 01/2020
1	Anemia 01/2020
1	Fatigue 01/2020
1	Cardiotoxicity 01/2019
1	Mental Disorders (Mental Disorder) 01/2018
1	Back Pain (Backache) 01/2018
1	Ileus 01/2013
1	Muscle Cramp (Cramp) 11/2011
1	Weight Loss (Weight Reduction) 11/2009
1	Weight Gain 11/2009
1	Pica (Geophagia) 08/2009
1	Infections 02/2004

Drug/Important Bio-Agent (IBA)

20	methylnaltrexone FDA Link 01/2022 - 05/2006
15	Opioid Analgesics (Opioids)IBA 01/2022 - 05/2006
7	Narcotic Antagonists (Opioid Antagonists)IBA 09/2021 - 05/2008
5	LaxativesIBA 01/2022 - 05/2008
4	Morphine (MS Contin)FDA LinkGeneric 01/2021 - 01/2017
4	brodalumabIBA 06/2020 - 01/2018
3	Rifaximin (L 105)FDA Link 06/2022 - 01/2017
3	Monoclonal AntibodiesIBA 06/2020 - 01/2018
3	AntigensIBA 01/2020 - 01/2014
2	Opioid Receptors (Opioid Receptor)IBA 01/2021 - 05/2008
2	Ustekinumab (CNTO 1275)FDA Link 06/2020 - 02/2020
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 01/2019
2	PSMA ADCIBA 01/2020 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 01/2014
2	mu Opioid Receptors (mu Opioid Receptor)IBA 11/2009 - 08/2009
1	TabletsIBA 06/2022
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 06/2022
1	AerosolsIBA 12/2021
1	Ribavirin (Virazole)FDA LinkGeneric 12/2021
1	SolutionsIBA 12/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	ElectrolytesIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	enzalutamideIBA 01/2020
1	abirateroneIBA 01/2020
1	Docetaxel (Taxotere)FDA Link 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Interleukin-17 ReceptorsIBA 01/2018
1	Methadone (Dolophine)FDA LinkGeneric 01/2018
1	auristatinIBA 01/2014
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2014
1	Biological ProductsIBA 01/2014
1	LeptinIBA 11/2009
1	Naloxone (Narcan)FDA LinkGeneric 11/2009
1	Anesthetics (Anesthetic Agents)IBA 09/2009
1	Protease Inhibitors (Protease Inhibitor)IBA 08/2009
1	KaolinIBA 08/2009
1	Ritonavir (Norvir)FDA Link 08/2009
1	EmeticsIBA 08/2009

Therapy/Procedure

9	Analgesia 01/2022 - 05/2006
4	Therapeutics 01/2020 - 02/2004
2	Castration 01/2020 - 01/2019
1	Retreatment 02/2020
1	Drug Therapy (Chemotherapy) 01/2019
1	Intravenous Infusions 01/2019
1	Colectomy 01/2013
1	Intraperitoneal Injections 11/2009
1	Investigational Therapies (Experimental Therapy) 05/2008